Gorgojo-Martinez, J.J.; Ferreira-Ocampo, P.J.; Galdón Sanz-Pastor, A.; Cárdenas-Salas, J.; Antón-Bravo, T.; Brito-Sanfiel, M.; Almodóvar-Ruiz, F.
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study. J. Clin. Med. 2023, 12, 4248.
https://doi.org/10.3390/jcm12134248
AMA Style
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, Almodóvar-Ruiz F.
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study. Journal of Clinical Medicine. 2023; 12(13):4248.
https://doi.org/10.3390/jcm12134248
Chicago/Turabian Style
Gorgojo-Martinez, Juan J., Pablo José Ferreira-Ocampo, Alba Galdón Sanz-Pastor, Jersy Cárdenas-Salas, Teresa Antón-Bravo, Miguel Brito-Sanfiel, and Francisca Almodóvar-Ruiz.
2023. "Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study" Journal of Clinical Medicine 12, no. 13: 4248.
https://doi.org/10.3390/jcm12134248
APA Style
Gorgojo-Martinez, J. J., Ferreira-Ocampo, P. J., Galdón Sanz-Pastor, A., Cárdenas-Salas, J., Antón-Bravo, T., Brito-Sanfiel, M., & Almodóvar-Ruiz, F.
(2023). Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study. Journal of Clinical Medicine, 12(13), 4248.
https://doi.org/10.3390/jcm12134248
